$23 billion dollar publicly-held global specialty pharmaceutical company with a product line that includes pharmaceuticals, biologics, medical devices, and over-the-counter consumer products empowered to make optimal executive-level project and portfolio management decisions. With a portfolio of clinical studies that fluctuates year over year depending on the portfolio, resource and cost constraints are a constant issue. Questions such as

Join for free to read